{"id":119117,"date":"2025-11-10T10:12:00","date_gmt":"2025-11-10T13:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/johnson-johnson-lanca-plataforma-varipulsetm-no-brasil-e-avanca-no-tratamento-da-fibrilacao-atrial\/"},"modified":"2025-11-10T10:12:00","modified_gmt":"2025-11-10T13:12:00","slug":"johnson-johnson-lanca-plataforma-varipulsetm-no-brasil-e-avanca-no-tratamento-da-fibrilacao-atrial","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/johnson-johnson-lanca-plataforma-varipulsetm-no-brasil-e-avanca-no-tratamento-da-fibrilacao-atrial\/","title":{"rendered":"Johnson &amp; Johnson lan\u00e7a plataforma VARIPULSE(TM) no Brasil e avan\u00e7a no tratamento da fibrila\u00e7\u00e3o atrial"},"content":{"rendered":"\n<div class=\"xn-content\">\n<p class=\"prntac\"><i>A plataforma VARIPULSE(TM) \u00e9 o primeiro sistema de abla\u00e7\u00e3o por campo pulsado (PFA) totalmente integrado ao sistema de mapeamento eletroanat\u00f4mico CARTO(TM) 3, projetado para promover efici\u00eancia, reprodutibilidade e precis\u00e3o nos procedimentos.<\/i><sup>  <i> <b>1<\/b>  <\/i>  <i>,<\/i>  <i> <b>i<\/b>  <\/i>  <i>,<\/i>  <i> <b>ii<\/b>  <\/i>  <i>,<\/i>  <i> <b>iii<\/b>  <\/i>  <i>,<\/i>  <i> <b>iv<\/b>  <\/i>  <i>,<\/i>  <i> <b>v<\/b>  <\/i>  <i>,<\/i>  <i> <b>vi<\/b>  <\/i>  <i>,<\/i>  <i> <b>vii<\/b>  <\/i>  <i>,<\/i>  <i> <b>viii<\/b>  <\/i>  <i>,<\/i>  <i> <b>ix<\/b>  <\/i><\/sup>\n <\/p>\n<p><span class=\"legendSpanClass\">S\u00c3O PAULO<\/span>, <span class=\"legendSpanClass\">10 de novembro de 2025<\/span> \/PRNewswire\/ &#8212; A Johnson &amp; Johnson MedTech, l\u00edder global no tratamento de arritmias card\u00edacas, anuncia o lan\u00e7amento da plataforma VARIPULSE(TM) no Brasil. A tecnologia \u00e9 utilizada em procedimentos de abla\u00e7\u00e3o por cateter para fibrila\u00e7\u00e3o atrial (FA), uma arritmia caracterizada por batimentos irregulares e, frequentemente, acelerados, causada por sinais el\u00e9tricos adicionais e descoordenados nos \u00e1trios.<sup>x<\/sup> A FA est\u00e1 associada a altera\u00e7\u00f5es estruturais no cora\u00e7\u00e3o decorrentes de condi\u00e7\u00f5es pr\u00e9-existentes e fatores de estilo de vidax<sup>,xi<\/sup> , e aumenta significativamente o risco de acidente vascular cerebral (AVC), insufici\u00eancia card\u00edaca e mortalidade.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n  <a href=\"https:\/\/mma.prnewswire.com\/media\/2554601\/Johnson_Johnson_MedTech_Logo.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2554601\/Johnson_Johnson_MedTech_Logo.jpg\" title=\"(PRNewsfoto\/Johnson &amp; Johnson MedTech)\" alt=\"(PRNewsfoto\/Johnson &amp; Johnson MedTech)\" \/>  <\/a>\n<\/p>\n<\/p><\/div>\n<p>A fibrila\u00e7\u00e3o atrial afeta cerca de 50 milh\u00f5es de pessoas no mundo<sup>xii<\/sup>, representando um impacto compar\u00e1vel ao da insufici\u00eancia card\u00edaca, que atinge mais de 64 milh\u00f5es globalmente<sup>xiii<\/sup>. Os sintomas e consequ\u00eancias cl\u00ednicas da FA comprometem a qualidade de vida dos pacientes. Entre os sintomas mais comuns est\u00e3o palpita\u00e7\u00f5es, fadiga, falta de ar, dor no peito e tontura<sup>xiv<\/sup>. Por ser uma condi\u00e7\u00e3o progressiva, a interven\u00e7\u00e3o precoce \u00e9 fundamental para reduzir o risco de AVC &#8212; respons\u00e1vel por 7,25 milh\u00f5es de mortes no mundo em 2021.<sup>xv<\/sup> A FA tamb\u00e9m aumenta o risco de insufici\u00eancia card\u00edaca e mortalidade cardiovascular<sup>xvi<\/sup>.<\/p>\n<p>A plataforma VARIPULSE(TM) \u00e9 a primeira tecnologia de PFA desenvolvida para integrar, em um \u00fanico fluxo de trabalho, a abla\u00e7\u00e3o e o mapeamento com o sistema CARTO(TM) 3. Essa tecnologia de mapeamento card\u00edaco eletroanat\u00f4mico 3D permite visualiza\u00e7\u00e3o em tempo real e oferece precis\u00e3o, efici\u00eancia, reprodutibilidade e acur\u00e1cia para m\u00e9dicos que tratam pacientes com fibrila\u00e7\u00e3o atrial<sup>xvii<\/sup>. Proporciona uma terapia segura, eficiente i<sup>,<\/sup>ii<sup>,<\/sup>iii<sup>,<\/sup>iv<sup>,<\/sup>v<sup>,<\/sup>vi<sup>,<\/sup>vii, e centrada no paciente, com m\u00ednima ou nenhuma exposi\u00e7\u00e3o \u00e0 fluoroscopia<sup>xviii,xix,xx<\/sup> sendo compat\u00edvel com seda\u00e7\u00e3o profunda e\/ou consciente.<sup>2,xxi,xxii<\/sup><\/p>\n<p><b>Evid\u00eancias cl\u00ednicas<\/b>\n <\/p>\n<p>Essa inova\u00e7\u00e3o \u00e9 respaldada por resultados cl\u00ednicos relevantes:<\/p>\n<ul type=\"disc\">\n<li>  <b> <i>inspIRE<\/i>  <\/b>: 80% dos pacientes permaneceram livres de recorr\u00eancia, sem eventos adversos prim\u00e1rios.<sup>xxiii<\/sup><\/li>\n<li>  <b> <i>admIRE<\/i>  <\/b>: taxa de sucesso prim\u00e1rio geral de 75%<sup>3<\/sup>, 100% dos pacientes obtiveram sucesso agudo no procedimento<sup>4<\/sup>, 43% tiveram alta no mesmo dia e 25% dos procedimentos foram realizados sem fluoroscopia<sup>5<\/sup>.<\/li>\n<li>  <b>VARIPURE<\/b> (em andamento, incluindo primeiros usu\u00e1rios): nenhum evento adverso grave ou complica\u00e7\u00f5es relacionadas \u00e0 plataforma, incluindo zero eventos neurovasculares ou espasmos coron\u00e1rios<sup>xxiv<\/sup>.<\/li>\n<\/ul>\n<p>&#8220;O lan\u00e7amento da plataforma VARIPULSE(TM) no Brasil \u00e9 um marco em nossa miss\u00e3o de trazer solu\u00e7\u00f5es inovadoras que melhorem o cuidado com o paciente&#8221;, afirma Alexandre Luque, Vice-presidente da Johnson &amp; Johnson MedTech no Brasil. &#8220;Ao combinar a abla\u00e7\u00e3o por campo pulsado com mapeamento avan\u00e7ado e intelig\u00eancia artificial, ajudamos os m\u00e9dicos a realizar procedimentos mais seguros, r\u00e1pidos e precisos.<\/p>\n<p>Diferentemente dos m\u00e9todos tradicionais de abla\u00e7\u00e3o, que utilizam calor ou frio, a PFA emprega pulsos curtos de energia para atuar sobre o tecido card\u00edaco, potencialmente reduzindo o risco de danos a estruturas adjacentes, como es\u00f4fago, veias pulmonares e nervo fr\u00eanico. At\u00e9 julho de 2025, a plataforma VARIPULSE(TM) j\u00e1 havia sido utilizada em mais de 15 mil procedimentos no mundo.<\/p>\n<p>&#8220;A introdu\u00e7\u00e3o da plataforma VARIPULSE(TM) no Brasil oferece uma nova e importante op\u00e7\u00e3o para o tratamento da fibrila\u00e7\u00e3o atrial&#8221;, afirma Dr. Cristiano Pisani<sup>6<\/sup>, eletrofisiologista do Instituto do Cora\u00e7\u00e3o do Hospital das Cl\u00ednicas da FMUSP, em S\u00e3o Paulo. &#8220;A experi\u00eancia cl\u00ednica inicial sugere que a combina\u00e7\u00e3o da abla\u00e7\u00e3o por campo pulsado com mapeamento 3D avan\u00e7ado pode nos ajudar a realizar procedimentos com maior precis\u00e3o e potencialmente reduzir riscos para estruturas pr\u00f3ximas. Como em qualquer nova tecnologia, \u00e9 essencial continuar avaliando seu desempenho em diferentes perfis de pacientes e garantir treinamento adequado para seu uso seguro e eficaz.&#8221;<\/p>\n<p><b>Sobre a plataforma VARIPULSE(TM)<\/b><\/p>\n<p>A plataforma VARIPULSE(TM) \u00e9 o sistema de abla\u00e7\u00e3o por campo pulsado da Johnson &amp; Johnson MedTech. A solu\u00e7\u00e3o totalmente integrada inclui o cateter VARIPULSE(TM), o gerador TRUPULSE(TM) e o software VARIPULSE(TM) para o sistema de mapeamento CARTO(TM) 3. A plataforma j\u00e1 est\u00e1 aprovada para uso nos Estados Unidos, Europa, \u00c1sia-Pac\u00edfico e Canad\u00e1.<\/p>\n<p><b>Solu\u00e7\u00f5es cardiovasculares da Johnson &amp; Johnson MedTech<\/b><\/p>\n<p>Em toda a Johnson &amp; Johnson, enfrentamos alguns dos desafios de sa\u00fade mais complexos e abrangentes do mundo. Por meio de um portf\u00f3lio cardiovascular que oferece aos profissionais de sa\u00fade mapeamento e navega\u00e7\u00e3o avan\u00e7ados, tecnologia miniaturizada e abla\u00e7\u00e3o precisa, estamos atuando em condi\u00e7\u00f5es com necessidades cl\u00ednicas significativas n\u00e3o atendidas, como insufici\u00eancia card\u00edaca, doen\u00e7a arterial coronariana, AVC e fibrila\u00e7\u00e3o atrial. Somos l\u00edderes globais em recupera\u00e7\u00e3o card\u00edaca, restaura\u00e7\u00e3o circulat\u00f3ria e tratamento de dist\u00farbios do ritmo card\u00edaco, al\u00e9m de emergente lideran\u00e7a em cuidados neurovasculares, comprometidos em enfrentar duas das principais causas de morte no mundo: insufici\u00eancia card\u00edaca e AVC. Para mais informa\u00e7\u00f5es, acesse <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=pt&amp;o=4553215-1&amp;h=68389557&amp;u=https%3A%2F%2Fbiosensewebster.com%2F&amp;a=biosensewebster.com\" target=\"_blank\" rel=\"nofollow\">biosensewebster.com<\/a><b>.<\/b><\/p>\n<p><b>Sobre a Johnson &amp; Johnson?<\/b>\n <\/p>\n<p> Na Johnson &amp; Johnson, acreditamos que a sa\u00fade \u00e9 tudo. Nossa for\u00e7a em inova\u00e7\u00e3o na \u00e1rea da sa\u00fade nos capacita a construir um mundo onde doen\u00e7as complexas s\u00e3o prevenidas, tratadas e curadas, onde os tratamentos s\u00e3o mais inteligentes e menos invasivos, e as solu\u00e7\u00f5es s\u00e3o personalizadas. Por meio de nossa expertise em Medicina Inovadora e MedTech, estamos em uma posi\u00e7\u00e3o \u00fanica para inovar em todo o espectro de solu\u00e7\u00f5es de sa\u00fade hoje, a fim de proporcionar as descobertas do amanh\u00e3 e impactar profundamente a sa\u00fade da humanidade. Saiba mais sobre a escala global e a profunda expertise do nosso setor de MedTech em solu\u00e7\u00f5es cardiovasculares, ortop\u00e9dicas, cir\u00fargicas e de vis\u00e3o em <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=pt&amp;o=4553215-1&amp;h=3517086818&amp;u=https%3A%2F%2Fthenext.jnjmedtech.com%2F&amp;a=https%3A%2F%2Fthenext.jnjmedtech.com%2F\" target=\"_blank\" rel=\"nofollow\">https:\/\/thenext.jnjmedtech.com\/<\/a>. Siga-nos no <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=pt&amp;o=4553215-1&amp;h=701337782&amp;u=https%3A%2F%2Fwww.instagram.com%2Fjnjmedtechbrasil%2F&amp;a=%40jnjmedtechbrasil\" target=\"_blank\" rel=\"nofollow\">@jnjmedtechbrasil<\/a> e no <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=pt&amp;o=4553215-1&amp;h=3666014478&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fjohnson-%26-johnson-medtech&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>. Biosense Webster, Inc. \u00e9 uma empresa da Johnson &amp; Johnson MedTech.<\/p>\n<p>(c) Johnson &amp; Johnson e suas afiliadas 2025. Todos os direitos reservados. BR_ELP_ALEL_405193<\/p>\n<p><sup>1<\/sup> When compared to procedures that did not use navigation systems. <br \/><sup>2<\/sup> Based on a subset of 29 deep sedation patients from the inspIRE study and 60 patients in inpsIRE study. Procedures completed under sedation vs general anesthesia had comparable safety rates and procedure times, demonstrating safety and procedural efficiency. <br \/><sup>3<\/sup> Primary effectiveness was defined as 12-month freedom from documented (symptomatic or asymptomatic) atrial tachyarrhythmia (atrial fibrillation [AF]\/atrial tachycardia [AT]\/atrial flutter [AF]) episodes of ?30 seconds duration based on rhythm monitoring during the post-blanking evaluation period (day 91-365), as well as freedom from other failure modes: failure to achieve entrance block in all PVs; &gt;1 repeat ablation for atrial tachyarrhythmia during the 3-month blanking period or any repeat ablation during the evaluation period; use of a nonstudy catheter to treat the PVs and\/or to ablate left atrial non-PV AF targets during the index procedure or to perform a repeat procedure during the 3-month blanking period; taking new or previously failed Class I\/III AADs at greater doses during the evaluation period; continuous AF\/AT\/AFL of unknown origin during the evaluation period; or direct-current cardioversion during the evaluation period for AF\/AT\/AFL recurrences. The protocol defined performance goal is 50%. <br \/><sup>4<\/sup> Acute procedural success was defined as the percent of participants with electrical isolation of all PVs with confirmed entrance block at the end of the procedure (n=255). <br \/><sup>5<\/sup> Visualization performed with ICE and the CARTO(TM) 3 System. <br \/><sup>6<\/sup> Dr. Cristiano Pisani serves as a consultant for Johnson &amp; Johnson but was not compensated for this announcement. <br \/><sup>i<\/sup> Duytschaever M, De Potter T, Grimaldi M, et al. Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter inspIRE Study. Circ Arrhythm Electrophysiol. 2023;16(3):e011780. doi:10.1161\/CIRCEP.122.011780 pg 4 <br \/><sup>ii<\/sup> Reddy VY, Calkins H, Mansour M, Wazni O, Di Biase L, Bahu M, Newton D, Liu CF, Sauer WH, Goyal S, Iyer V, Nair D, Athill C, Hussein A, Whalen P, Melby D, Natale A; AdmIRE Trial Investigators. Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial. Circulation. 2024 Oct 8 pg 8 <br \/><sup>iii<\/sup> Anter, E., Mansour, M., Nair, D.G. et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med 30, 2303-2310 (2024). <a href=\"https:\/\/doi.org\/10.1038\/s41591-024-03022-6\" rel=\"nofollow\">https:\/\/doi.org\/10.1038\/s41591-024-03022-6<\/a> pg 2 <br \/><sup>iv<\/sup> Reddy VY, Lehmann JW, Gerstenfeld EP, Mugglin AS, Schneider CW, Achyutha AB, Mansour M. A randomized controlled trial of pulsed field ablation versus standard-of-care ablation for paroxysmal atrial fibrillation: The ADVENT trial rationale and design. Heart Rhythm O2. 2023 Mar 8;4(5):317-328. doi: 10.1016\/j.hroo.2023.03.001. PMID: 37323994; PMCID: PMC10264259. Pg 6 <br \/><sup>v<\/sup> VOLT CE Mark Study: Long-term safety and effectiveness of de novo PVI intreating AF. pg 3 <br \/><sup>vi<\/sup> Scherr D, Turagam MK, Maury P, Blaauw Y, van der Voort P, Neuzil P, et al. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study. Europace. 2025;2025(1):euaf012. doi:10.1093\/europace\/euaf012. Pg 4 results section <br \/><sup>vii<\/sup> Seemala SKR, Musikantow DR, Perdomo C, Malyshev Y, Ambesh P, Saleem M, et al. Pulsed field ablation (PFA) to treat atrial fibrillation and related arrhythmias: one-year outcomes of the VIRTUE trial. Poster PO-FP-006. Pg 1 <br \/><sup>viii<\/sup> Fink T, Sciacca V, Bannmann K, et al. First experience using a novel variable loop catheter for mapping and pulsed field ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2025 May;48(5):471-479. doi:10.1111\/pace.15177. Epub 2025 Mar 28. PMID:40153431; PMCID:PMC12063197 <br \/><sup>ix<\/sup> Fink T, Sciacca V, Bannmann K, et al. First experience using a novel variable loop catheter for mapping and pulsed field ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2025 Mar 28. doi:10.1111\/pace.15177. Epub ahead of print. PMID: 40153431. <br \/><sup>x<\/sup> Laizzo PA. Handbook of Cardiac Anatomy, Physiology, and Devices. 2015. Springer Science+Business Media. LLC: Switzerland <br \/><sup>xi<\/sup> Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017;120(9):1501-1517 <br \/><sup>xii<\/sup> Tan S, Zhou J, Veang T, Lin Q, Liu Q. Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046&#8211;a systematic analysis of the Global Burden of Disease Study 2021. EP Europace. 2025;27(2):euaf027. doi:10.1093\/europace\/euaf027 <br \/><sup>xiii<\/sup> Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJSC. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272-3287. doi:10.1093\/cvr\/cvac013 <br \/><sup>xiv<\/sup> American Heart Association . (2024, August 12). <i>What are the symptoms of atrial fibrillation?<\/i>. <a href=\"http:\/\/www.heart.org\" rel=\"nofollow\">www.heart.org<\/a>. <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=pt&amp;o=4553215-1&amp;h=351514595&amp;u=https%3A%2F%2Fwww.heart.org%2Fen%2Fhealth-topics%2Fatrial-fibrillation%2Fwhat-are-the-symptoms-of-atrial-fibrillation-afib-or-af&amp;a=https%3A%2F%2Fwww.heart.org%2Fen%2Fhealth-topics%2Fatrial-fibrillation%2Fwhat-are-the-symptoms-of-atrial-fibrillation-afib-or-af\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.heart.org\/en\/health-topics\/atrial-fibrillation\/what-are-the-symptoms-of-atrial-fibrillation-afib-or-af<\/a> <br \/><sup><sup>xv<\/sup><\/sup> Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, et?al.; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 Heart Disease &amp; Stroke Statistics Update Fact Sheet: Global Burden of Disease. American Heart Association; 2025. (Based on data from the 2025 Heart Disease &amp; Stroke Statistics: A Report of US and Global Data published in Circulation) <br \/><sup>xvi<\/sup> Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024 Jan 2;149(1):e167]. Circulation. 2024;149(1):e1-e156. doi:10.1161\/CIR.0000000000001193 <br \/><sup>xvii<\/sup> Di Biase L, Zou F, Lin AN, et al. Feasibility of Three-Dimensional Artificial Intelligence Algorithm Integration with Intracardiac Echocardiography for Left Atrial Imaging During Atrial Fibrillation Catheter Ablation. Europace. 2023 Aug 2;25(9):euad211. <br \/><sup>xviii<\/sup> Debreceni D, Janosi K, Bocz B, et al. (2023). Zero fluoroscopy catheter ablation for atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med;10:1178783. doi: 10.3389\/fcvm.2023.1178783 <br \/><sup>xix<\/sup> Rajendra A, Hunter TD, Morales GX, et al. (2023). Steerable sheath visualizable under 3D electroanatomical mapping facilitates paroxysmal atrial fibrillation ablation with minimal fluoroscopy. J Interv Card Electrophysiol;66(2):381-388. doi: 10.1007\/s10840-022-01332-8. <br \/><sup>xx<\/sup> Tahin T, Riba A, Nemeth B, et al. (2021). Implementation of a zero fluoroscopic workflow using a simplified intracardiac echocardiography guided method for catheter ablation of atrial fibrillation, including repeat procedures. BMC Cardiovasc Disord;21(1):407. doi: 10.1186\/s12872-021-02219-8. <br \/><sup>xxi<\/sup> Grimaldi M, Quadrini F, Caporusso N, et al. Deep sedation protocol during atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter. Europace. 2023;25(9):euad222. doi:10.1093\/europace\/euad222. PMID: 37470452; PMCID: PMC10434733. <br \/><sup><sup>xxii<\/sup><\/sup> De Potter T, Grimaldi M, Duytschaever M, Anic A, Vijgen J, Neuzil P, Van Herendael H, Verma A, Skanes A, Scherr D, P\u00fcrerfellner H, Rackauskas G, Jais P, Reddy VY, et al; inspIRE Trial Investigators. Predictors of success for pulmonary vein isolation with pulsed-field ablation using a variable-loop catheter with 3D mapping integration: complete 12-month outcomes from inspIRE. Circ Arrhythm Electrophysiol. 2024;17(5):e012667. doi:10.1161\/CIRCEP.123.012667. Epub 2024 Apr 24. PMID: 38655693; PMCID: PMC11111320.<br \/><sup>xxiii<\/sup> Reddy V, Grimaldi M, Duytschaever M, Anic A. Predictors of Success for Pulmonary Vein Isolation with Pulsed Field Ablation Using a Variable Loop Catheter with 3D Mapping Integration: Complete 12-month outcomes from inspIRE [abstract]. In: AF Symposium.; February 2-4; Boston.<br \/><sup>xxiv<\/sup> Bessi\u00e8re F, Kronborg MB, Sommer P, et al. Evaluating Safety Profile and Learning Curve With a Pulsed Field Ablation Variable Loop Circular Catheter in Procedures for AF: Observations From a Prospective, Multicenter, Postmarket Clinical Trial. Presented at HRS 2025; April 27, 2025; San Diego, CA.<\/p>\n<p><b>Media contacts:<\/b><br \/>\n<br \/>Silvia Sim\u00f5es, <a href=\"mailto:ssimoesp@its.jnj.com\" target=\"_blank\" rel=\"nofollow\">ssimoesp@its.jnj.com<\/a> <\/p>\n<p>Logo &#8211;  <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=pt&amp;o=4553215-1&amp;h=4141288121&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2554601%2F5610338%2FJohnson_Johnson_MedTech_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2554601%2F5610338%2FJohnson_Johnson_MedTech_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2554601\/5610338\/Johnson_Johnson_MedTech_Logo.jpg<\/a> <\/p>\n<p id=\"PURL\">\n<img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=PT19182&amp;sd=2025-11-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/johnson--johnson-lanca-plataforma-varipulse-no-brasil-e-avanca-no-tratamento-da-fibrilacao-atrial-302609085.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/johnson&#8211;johnson-lanca-plataforma-varipulse-no-brasil-e-avanca-no-tratamento-da-fibrilacao-atrial-302609085.html<\/a><\/p>\n<p>FONTE Johnson &amp; Johnson MedTech<\/p>\n<\/p><\/div>\n<p>  <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT19182&amp;Transmission_Id=202511100800PR_NEWS_LATAM____PT19182&amp;DateId=20251110\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n<p><strong>T\u00f3picos Relacionados:<\/strong> M\u00e9dico \/ Farmac\u00eautico, Equipamento M\u00e9dico, Sa\u00fade\/Hospitais<\/p>\n<p>A <b>OESP<\/b> n\u00e3o \u00e9(s\u00e3o) respons\u00e1vel(is) por erros, incorre\u00e7\u00f5es, atrasos ou quaisquer decis\u00f5es tomadas por seus clientes com base nos Conte\u00fados ora disponibilizados, bem como tais Conte\u00fados n\u00e3o representam a opini\u00e3o da <b>OESP<\/b> e s\u00e3o de inteira responsabilidade da <b>PR Newswire Ltda<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"A plataforma VARIPULSE(TM) \u00e9 o primeiro sistema de abla\u00e7\u00e3o por campo pulsado (PFA) totalmente integrado ao sistema de mapeamento eletroanat\u00f4mico CARTO(TM) 3, projetado para promover efici\u00eancia,","protected":false},"author":1,"featured_media":119118,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[27],"tags":[4337,4339,4338],"class_list":["post-119117","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-prnewswire","tag-a-johnson-johnson-medtech","tag-anuncia-o-lancamento-da-plataforma-varipulsetm-no-brasil-a-tecnologia-e-utilizada-em-procediment","tag-lider-global-no-tratamento-de-arritmias-cardiacas"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/119117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=119117"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/119117\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media\/119118"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=119117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=119117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=119117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}